Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.72 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517545 | 0.84 | NR3C1 (1.00) | NR3C1GLO1SLC40A1 | |
| SCHEMBL2608852 | 0.70 | NR3C1 (0.54) | NR3C1 | |
| SCHEMBL30523468 | 0.68 | NR3C1 (0.52) | NR3C1ALDH1A1 | |
| SCHEMBL4524906 | 0.68 | NR3C1 (0.52) | NR3C1 | |
| Hydrochloric Acid SCHEMBL29387602 | 0.67 | NR3C1 (0.51) | NR3C1ALDH1A1 | |
| SCHEMBL4517669 | 0.66 | NR3C1 (0.73) | NR3C1ALDH1A1 | |
| SCHEMBL13911254 | 0.66 | PSIP1 (0.50) | GLO1SLC40A1PTGDR2 | |
| SCHEMBL13978708 | 0.65 | ABCB1 (0.55) | NR3C1ALDH1A1 | |
| SCHEMBL29296544 | 0.65 | NR1H2 (0.46) | NR3C1PTGDR2ALDH1A1 | |
| SCHEMBL4516862 | 0.65 | NR3C1 (1.00) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885GLO1 2554/4885SLC40A1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.